277 related articles for article (PubMed ID: 26024727)
1. Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting.
Weiss D; Knight R; Zhou S; Palmisano M; Chen N
Clin Drug Investig; 2015 Jul; 35(7):455-61. PubMed ID: 26024727
[TBL] [Abstract][Full Text] [Related]
2. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Malhotra B; Alvey C; Gong J; Li X; Duczynski G; Gandelman K
Br J Clin Pharmacol; 2011 Aug; 72(2):257-62. PubMed ID: 21496065
[TBL] [Abstract][Full Text] [Related]
3. Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects.
Yin OQ; Gallagher N; Fischer D; Zhao L; Zhou W; Leroy E; Golor G; Schran H
Clin Drug Investig; 2011; 31(3):169-79. PubMed ID: 21184622
[TBL] [Abstract][Full Text] [Related]
4. Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin.
Stockis A; van Lier JJ; Cawello W; Kumke T; Eckhardt K
Epilepsia; 2013 Jul; 54(7):1161-6. PubMed ID: 23614393
[TBL] [Abstract][Full Text] [Related]
5. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin.
Ragueneau-Majlessi I; Levy RH; Meyerhoff C
Epilepsy Res; 2001 Nov; 47(1-2):55-63. PubMed ID: 11673021
[TBL] [Abstract][Full Text] [Related]
6. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
[TBL] [Abstract][Full Text] [Related]
7. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
[TBL] [Abstract][Full Text] [Related]
8. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin.
Tiseo PJ; Foley K; Friedhoff LT
Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):45-50. PubMed ID: 9839766
[TBL] [Abstract][Full Text] [Related]
9. The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.
Schwartz JI; Bugianesi KJ; Ebel DL; De Smet M; Haesen R; Larson PJ; Ko A; Verbesselt R; Hunt TL; Lins R; Lens S; Porras AG; Dieck J; Keymeulen B; Gertz BJ
Clin Pharmacol Ther; 2000 Dec; 68(6):626-36. PubMed ID: 11180023
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin.
Padhi D; Sullivan JT
Drugs R D; 2007; 8(2):79-87. PubMed ID: 17324005
[TBL] [Abstract][Full Text] [Related]
11. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
Gu N; Kim BH; Lim KS; Kim SE; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
[TBL] [Abstract][Full Text] [Related]
12. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers.
Macha S; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Diabetes Obes Metab; 2013 Apr; 15(4):316-23. PubMed ID: 23094794
[TBL] [Abstract][Full Text] [Related]
13. Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjects.
Dingemanse J; Hoever P
Drugs R D; 2013 Jun; 13(2):145-51. PubMed ID: 23737453
[TBL] [Abstract][Full Text] [Related]
14. Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.
Moore KT; Byra W; Vaidyanathan S; Natarajan J; Ariyawansa J; Salih H; Turner KC
Br J Clin Pharmacol; 2015 Jun; 79(6):907-17. PubMed ID: 25475601
[TBL] [Abstract][Full Text] [Related]
15. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Van Hecken A; Depré M; Verbesselt R; Wynants K; De Lepeleire I; Arnout J; Wong PH; Freeman A; Holland S; Gertz B; De Schepper PJ
J Clin Pharmacol; 1999 May; 39(5):495-500. PubMed ID: 10234597
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects.
Jindal D; Tandon M; Sharma S; Pillai KK
Eur J Clin Pharmacol; 2005 Oct; 61(9):621-5. PubMed ID: 16133549
[TBL] [Abstract][Full Text] [Related]
17. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
Schwartz JI; Dunbar S; Yuan J; Li S; Gipson A; Rosko K; Johnson-Levonas AO; Lasseter KC; Addy C; Stoch AS; Wagner JA
Adv Ther; 2008 Nov; 25(11):1175-90. PubMed ID: 18989636
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.
Walker G; Mandagere A; Dufton C; Venitz J
Br J Clin Pharmacol; 2009 May; 67(5):527-34. PubMed ID: 19552747
[TBL] [Abstract][Full Text] [Related]
19. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
Wright DH; Herman GA; Maes A; Liu Q; Johnson-Levonas AO; Wagner JA
J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
[TBL] [Abstract][Full Text] [Related]
20. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin.
Depré M; Van Hecken A; Oeyen M; De Lepeleire I; Laethem T; Rothenberg P; Petty KJ; Majumdar A; Crumley T; Panebianco D; Bergman A; de Hoon JN
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):341-6. PubMed ID: 15983826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]